Benjamin Ruprecht
Benjamin Ruprecht
Covant Tx
Verified email at
Cited by
Cited by
The target landscape of clinical kinase drugs
S Klaeger, S Heinzlmeir, M Wilhelm, H Polzer, B Vick, PA Koenig, ...
Science 358 (6367), eaan4368, 2017
DMSO enhances electrospray response, boosting sensitivity of proteomic experiments
H Hahne, F Pachl, B Ruprecht, SK Maier, S Klaeger, D Helm, G Médard, ...
Nature methods 10 (10), 989-991, 2013
Optimized chemical proteomics assay for kinase inhibitor profiling
G Médard, F Pachl, B Ruprecht, S Klaeger, S Heinzlmeir, D Helm, H Qiao, ...
Journal of proteome research 14 (3), 1574-1586, 2015
Comprehensive and reproducible phosphopeptide enrichment using iron immobilized metal ion affinity chromatography (Fe-IMAC) columns
B Ruprecht, H Koch, G Medard, M Mundt, B Kuster, S Lemeer
Molecular & Cellular Proteomics 14 (1), 205-215, 2015
Ion mobility tandem mass spectrometry enhances performance of bottom-up proteomics
D Helm, JPC Vissers, CJ Hughes, H Hahne, B Ruprecht, F Pachl, A Grzyb, ...
Molecular & Cellular Proteomics 13 (12), 3709-3715, 2014
A bead-based western for high-throughput cellular signal transduction analyses
F Treindl, B Ruprecht, Y Beiter, S Schultz, A Döttinger, A Staebler, ...
Nature communications 7 (1), 12852, 2016
Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis
B Ruprecht, EA Zaal, J Zecha, W Wu, CR Berkers, B Kuster, S Lemeer
Cancer research 77 (8), 1842-1853, 2017
Omomyc reveals new mechanisms to inhibit the MYC oncogene
MJ Demma, C Mapelli, A Sun, S Bodea, B Ruprecht, S Javaid, D Wiswell, ...
Molecular and Cellular Biology, 2019
Proteome activity landscapes of tumor cell lines determine drug responses
M Frejno, C Meng, B Ruprecht, T Oellerich, S Scheich, K Kleigrewe, ...
Nature communications 11 (1), 3639, 2020
Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity
S Lemeer, C Zörgiebel, B Ruprecht, K Kohl, B Kuster
Journal of proteome research 12 (4), 1723-1731, 2013
Chemical proteomics and structural biology define EPHA2 inhibition by clinical kinase drugs
S Heinzlmeir, D Kudlinzki, S Sreeramulu, S Klaeger, SL Gande, V Linhard, ...
ACS chemical biology 11 (12), 3400-3411, 2016
Pharmacoproteomic characterisation of human colon and rectal cancer
M Frejno, R Zenezini Chiozzi, M Wilhelm, H Koch, R Zheng, S Klaeger, ...
Molecular systems biology 13 (11), 951, 2017
Proteomic analysis of phosphorylation in cancer
B Ruprecht, S Lemeer
Expert review of proteomics 11 (3), 259-267, 2014
High pH reversed-phase micro-columns for simple, sensitive, and efficient fractionation of proteome and (TMT labeled) phosphoproteome digests
B Ruprecht, J Zecha, DP Zolg, B Kuster
Proteomics: Methods and Protocols, 83-98, 2017
Evaluation of kinase activity profiling using chemical proteomics
B Ruprecht, J Zecha, S Heinzlmeir, G Medard, S Lemeer, B Kuster
ACS chemical biology 10 (12), 2743-2752, 2015
Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry
T Dixon, D MacPherson, B Mostofian, T Dauzhenka, S Lotz, D McGee, ...
Nature communications 13 (1), 5884, 2022
Characterization of a chemical affinity probe targeting Akt kinases
F Pachl, P Plattner, B Ruprecht, G Medard, N Sewald, B Kuster
Journal of Proteome Research 12 (8), 3792-3800, 2013
A mass spectrometry-based proteome map of drug action in lung cancer cell lines
B Ruprecht, J Di Bernardo, Z Wang, X Mo, O Ursu, M Christopher, ...
Nature Chemical Biology 16 (10), 1111-1119, 2020
Decrypting drug actions and protein modifications by dose-and time-resolved proteomics
J Zecha, FP Bayer, S Wiechmann, J Woortman, N Berner, J Müller, ...
Science 380 (6640), 93-101, 2023
Optimized enrichment of phosphoproteomes by Fe-IMAC column chromatography
B Ruprecht, H Koch, P Domasinska, M Frejno, B Kuster, S Lemeer
Proteomics: Methods and Protocols, 47-60, 2017
The system can't perform the operation now. Try again later.
Articles 1–20